Table of Contents

Front Matter.
Historical Perspectives on Child and Adolescent Psychopharmacology / Samuel Gershon.
Pharmacoepidemiology of Psychotropic Medications in Youth / Daniel J Safer, Julie Magno Zito.
Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry / C Lindsay Devane.
The Use of Generic Drugs in Pediatric Psychopharmacology / Richard I Shader, Christopher-Paul Milne.
Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology / David J Edwards.
Psychostimulants / Steven R Pliszka.
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders / Charlotte M Heleniak, Tejal Kaur, Kareem D Ghalib, Moira A Rynn.
Selective Serotonin Reuptake Inhibitors (SSRIs) / Dara Sakolsky, Boris Birmaher.
Novel (Atypical) Antidepressants / Heidi R Bruty, Graham J Emslie, Paul Croarkin.
Antipsychotic Agents / Brieana M Rowles, John L Hertzer, Robert L Findling.
Lithium / Garrett M Sparks, David A Axelson.
Anticonvulsants Used in Child and Adolescent Psychiatric Disorders / Mani Pavuluri, Tushita Mayanil.
Anxiolytics / Barbara J Coffey, Amanda L Zwilling.
Adrenergic Agents in Child and Adolescent Psychiatry / Lawrence David Scahill.
Atypical Psychopharmacologic Strategies / Jess Shatkin, Aron Janssen.
Psychopharmacology in Preschool Children / Mini Tandon, Joan Luby.
Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents / Gagan Joshi, Anna M Georgiopoulos.
Index. This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.
This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.
Gershon, Samuel;Rosenberg, David R
-
John Wiley & Sons, Inc.
2012
3rd ed.
9781119958321
9780470973769
RefWorks